Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Bankerson--Dan Bannister

No, by "full" I mean full. Per my understanding of the MA, if PTSC is sold/merged/changes ownership, they forfeit any and all rights to the MMP to the other parties to the agreement (TPL/Moore).

As for your very recent question to ccraider re: the scenario he described, etc., I suspect the ramifications would be minimal at best. Just ask Apple, IBM, MS, etc. The other thing to consider is that the MMP has already been licensed to a slew of corporations. Perhaps another way to look at it is that Alliacense pretty much has monopolistic control of this essential bit of IP.

Hope this helps!

SGE

Share
New Message
Please login to post a reply